Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
UCHealth pharmacist Marissa Kim prepares a dose of the Pfizer-BioNTech COVID-19 vaccine on Feb. 20 in Denver, Colorado. Photo: Michael Ciaglo/Getty Images
Moderna and Pfizer plan to significantly boost vaccine shipments to the U.S. government by this spring, according to written testimony from company executives released Tuesday ahead of a House committee hearing on vaccines.
Where it stands: Pfizer expects to increase its weekly vaccine delivery from 4-5 million doses at the start of February to more than 13 million doses by mid-March, said John Young, Pfizer's chief business officer.
- Moderna is working to deliver more than 40 million doses per month, doubling its current supply, and aims to ship another 100 million doses by the end of May, said Moderna president Stephen Hoge.
Between the lines: Both companies are studying potential booster shots in response to emerging coronavirus variants. Their vaccines have shown to be effective against the highly transmissible strains first seen in the U.K. and South Africa.
- Pfizer is also studying booster effects in trial participants who have been fully vaccinated, Young said.
- Moderna hopes to provide vaccinations to adolescents by the fall and is currently testing its vaccine's safety for children ages 12 to 18.
Be smart: The more Americans that are fully vaccinated, the faster that herd immunity will be reached — making it more difficult for the virus to spread.
Of note: Johnson & Johnson aims to make 20 million doses of its vaccine available to the government by the end of March, J&J vice president Richard Nettles testified on Tuesday. The company's one-shot vaccine is awaiting emergency use authorization from the FDA.
Go deeper on vaccines with our video short course.